Context Therapeutics (NASDAQ:CNTX) Stock Rating Upgraded by Zacks Research

Context Therapeutics (NASDAQ:CNTX) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Tuesday, Zacks reports.

Other analysts have also recently issued reports about the company. Lifesci Capital cut Context Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. Citigroup reiterated an “outperform” rating on shares of Context Therapeutics in a research note on Thursday, August 6th. Weiss Ratings raised Context Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, October 15th. Finally, Wall Street Zen cut Context Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Monday, July 20th. Six equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $6.40.

Context Therapeutics Price Performance

Shares of CNTX opened at $0.22 on Tuesday. The firm has a 50-day moving average of $0.29 and a 200-day moving average of $1.39. Context Therapeutics has a one year low of $0.18 and a one year high of $3.62. The company has a market cap of $19.86 million, a PE ratio of -0.47 and a beta of 1.77.

Context Therapeutics (NASDAQ:CNTX) last issued its earnings results on Tuesday, November 10th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. Analysts expect that Context Therapeutics will post -0.47 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CNTX. Octagon Capital Advisors LP bought a new stake in shares of Context Therapeutics during the first quarter worth approximately $13,755,000. Blue Owl Capital Holdings LP acquired a new position in shares of Context Therapeutics in the second quarter valued at approximately $1,625,000. BlackRock Inc. bought a new position in shares of Context Therapeutics during the second quarter worth approximately $3,417,000. ADAR1 Capital Management LLC bought a new position in shares of Context Therapeutics during the second quarter worth approximately $416,000. Finally, Russell Investments Group Ltd. increased its stake in shares of Context Therapeutics by 8,907.7% during the third quarter. Russell Investments Group Ltd. now owns 671,074 shares of the company’s stock worth $202,000 after purchasing an additional 663,624 shares during the period. 14.03% of the stock is owned by institutional investors.

About Context Therapeutics

Context Therapeutics Inc. (NASDAQ:CNTX) is a clinical-stage biotechnology company focused on developing targeted immunotherapies for solid tumors. The company’s approach is centered on T-cell-engaging bispecific antibodies, which are designed to direct the body’s immune cells toward cancer cells expressing specific tumor-associated antigens. Context’s lead program is CTIM-76, an investigational bispecific antibody that targets Claudin 6 (CLDN6) on tumor cells and CD3 on T cells. The program is being developed for patients with CLDN6-positive advanced solid tumors, including ovarian, endometrial, testicular and other cancers.